#Bluejay #BluejayTherapeutics #phase3trial #brelovitug #BJT778 #hepatitisD #AZURE2study #CHD #hepatitisDvirus #cirrhosis #livercancer #viralhepatitis #liverdisease #BreakthroughTherapydesignation #FDA #PRIMEdesignation #Orphanstatus #OrphanDrug #EMA
pharmatimes.com/news/bluejay...
pharmatimes.com/news/bluejay...
Bluejay begins phase 3 trial of brelovitug for hepatitis D - PharmaTimes
First patient enrolled in AZURE-2 study comparing brelovitug to Hepcludex
pharmatimes.com
September 10, 2025 at 12:03 PM
Bluejay Therapeutics’ investigational therapy, brelovitug, offers weekly self-administered injections and will be studied against the only approved treatment outside the US. #IDsky #Medsky
First Patient Enrolled in Phase 3 Study for Hepatitis D Treatment
Bluejay Therapeutics’ investigational therapy, brelovitug, offers weekly self-administered injections and will be studied against the only approved treatment outside the US.
www.contagionlive.com
September 8, 2025 at 3:59 PM
ICYMI: Bluejay Therapeutics has dosed the first patient in the AZURE-1 trial, evaluating brelovitug (BJT-778) as a monotherapy for chronic hepatitis D, the most severe form of viral hepatitis. Phase 2 data showed 100% virologic response. #IDsky #MEDsky
www.contagionlive.com/view/investi...
www.contagionlive.com/view/investi...
Investigational Monoclonal Antibody for Chronic Hepatitis D Treatment Begins Clinical Trial
The study, being conducted by Bluejay Therapeutics, will evaluate the efficacy and safety of its monoclonal antibody, brelovitug (also known as BJT-778), compared to delayed treatment.
www.contagionlive.com
April 2, 2025 at 4:44 PM
ICYMI: Bluejay Therapeutics has dosed the first patient in the AZURE-1 trial, evaluating brelovitug (BJT-778) as a monotherapy for chronic hepatitis D, the most severe form of viral hepatitis. Phase 2 data showed 100% virologic response. #IDsky #MEDsky
www.contagionlive.com/view/investi...
www.contagionlive.com/view/investi...
The study, being conducted by Bluejay Therapeutics, will evaluate the efficacy and safety of its monoclonal antibody, brelovitug (also known as BJT-778), compared to delayed treatment. #hepatitis #IDsky
Investigational Monoclonal Antibody for Chronic Hepatitis D Treatment Begins Clinical Trial
The study, being conducted by Bluejay Therapeutics, will evaluate the efficacy and safety of its monoclonal antibody, brelovitug (also known as BJT-778), compared to delayed treatment.
www.contagionlive.com
March 27, 2025 at 1:32 PM
The study, being conducted by Bluejay Therapeutics, will evaluate the efficacy and safety of its monoclonal antibody, brelovitug (also known as BJT-778), compared to delayed treatment. #hepatitis #IDsky
“Brelovitug (BJT-778) is a fully human immunoglobulin G1 monoclonal antibody designed to target hepatitis B surface antigen and neutralize and remove HBV and HDV virions.” www.healio.com/news/gastroe...
Bluejay Therapeutics’ brelovitug secures FDA breakthrough status for chronic HDV
The FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for the treatment of chronic hepatitis delta, for which no approved therapies currently exist in the U.S....
www.healio.com
January 23, 2025 at 7:04 PM
“Brelovitug (BJT-778) is a fully human immunoglobulin G1 monoclonal antibody designed to target hepatitis B surface antigen and neutralize and remove HBV and HDV virions.” www.healio.com/news/gastroe...
ICYMI: Today, the FDA granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta.
Learn more:
www.hcplive.com/view/brelovi...
Learn more:
www.hcplive.com/view/brelovi...
January 22, 2025 at 2:22 AM
ICYMI: Today, the FDA granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta.
Learn more:
www.hcplive.com/view/brelovi...
Learn more:
www.hcplive.com/view/brelovi...